Blocking NF-κB and Akt by Hsp90 inhibition sensitizes Smac mimetic compound 3-induced extrinsic apoptosis pathway and results in synergistic cancer cell death

Apoptosis

Volumn 16, Issue 1, 2011, Pages 45-54

  Bai, Lang ^a,b   Xu, Shanling ^a   Chen, Wenshu ^a   Li, Zi ^a   Wang, Xia ^c   Tang, Hong ^b   Lin, Yong ^a  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^b SICHUAN UNIVERSITY   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

Akt; Apoptosis; Cytotoxicity; Hsp90; NF B; Smac mimetic

Indexed keywords

HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE B; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SMAC MIMETIC COMPOUND 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE REPRESSION; HUMAN; HUMAN TISSUE; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN TARGETING; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SYNERGISM; GENE EXPRESSION; HETEROCYCLIC COMPOUNDS, 2-RING; HSP90 HEAT-SHOCK PROTEINS; HUMANS; I-KAPPA B KINASE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; LUNG NEOPLASMS; MITOCHONDRIAL PROTEINS; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; RIFABUTIN; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 79951545532     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-010-0542-4     Document Type: Article

References (38)

1. D Hanahan RA Weinberg 2000 The hallmarks of cancer Cell 100 57 70 1:CAS:528:DC%2BD3cXks1CktA%3D%3D 10.1016/S0092-8674(00)81683-9 10647931 (Pubitemid 30046295)
2. X Jin Z Wang L Qiu, et al. 2008 Potential biomarkers involving IKK/RelA signal in early stage non-small cell lung cancer Cancer Sci 99 582 589 1:CAS:528:DC%2BD1cXjt1ehsL4%3D 10.1111/j.1349-7006.2007.00713.x 18215193 (Pubitemid 351228577)
3. M Karin FR Greten 2005 NF-kappaB: linking inflammation and immunity to cancer development and progression Nat Rev Immunol 5 749 759 1:CAS:528:DC%2BD2MXhtVGrurvL 10.1038/nri1703 16175180 (Pubitemid 41400849)
4. J Li H Jia L Xie, et al. 2009 Association of constitutive nuclear factor-kappaB activation with aggressive aspects and poor prognosis in cervical cancer Int J Gynecol Cancer 19 1421 1426 10.1111/IGC.0b013e3181b70445 20009901
5. M Karin 2006 Nuclear factor-kappaB in cancer development and progression Nature 441 431 436 1:CAS:528:DC%2BD28XkvVyrsrw%3D 10.1038/nature04870 16724054 (Pubitemid 44050137)
6. MS Hayden S Ghosh 2008 Shared principles in NF-kappaB signaling Cell 132 344 362 1:CAS:528:DC%2BD1cXivVahtbY%3D 10.1016/j.cell.2008.01.020 18267068 (Pubitemid 351192002)
7. Y Lin L Bai W Chen S Xu 2010 The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy Expert Opin Ther Targets 14 45 55 1:CAS:528:DC%2BD1MXhsFCitbvJ 10.1517/14728220903431069 20001209
8. BB Aggarwal 2004 Nuclear factor-kappaB: the enemy within Cancer Cell 6 203 208 1:CAS:528:DC%2BD2cXot1Kis78%3D 10.1016/j.ccr.2004.09.003 15380510 (Pubitemid 39222032)
9. C Garcia-Echeverria WR Sellers 2008 Drug discovery approaches targeting the PI3K/Akt pathway in cancer Oncogene 27 5511 5526 1:CAS:528: DC%2BD1cXhtFWiur3J 10.1038/onc.2008.246 18794885
10. JQ Cheng CW Lindsley GZ Cheng H Yang SV Nicosia 2005 The Akt/PKB pathway: molecular target for cancer drug discovery Oncogene 24 7482 7492 1:CAS:528:DC%2BD2MXht1Wis7vJ 10.1038/sj.onc.1209088 16288295 (Pubitemid 41637988)
11. D Sarker AH Reid TA Yap JS de Bono 2009 Targeting the PI3K/AKT pathway for the treatment of prostate cancer Clin Cancer Res 15 4799 4805 1:CAS:528:DC%2BD1MXptl2gsLo%3D 10.1158/1078-0432.CCR-08-0125 19638457
12. W Chen X Wang J Zhuang L Zhang Y Lin 2007 Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in non-small cell lung cancer cells Carcinogenesis 28 2114 2121 1:CAS:528:DC%2BD2sXhtFeqsL7E 10.1093/carcin/bgm133 17548900 (Pubitemid 47543370)
13. RM Memmott PA Dennis 2009 Akt-dependent and -independent mechanisms of mTOR regulation in cancer Cell Signal 21 656 664 1:CAS:528:DC%2BD1MXisFWjs7c%3D 10.1016/j.cellsig.2009.01.004 19166931
14. W Chen L Bai X Wang S Xu SA Belinsky Y Lin 2010 Acquired activation of the Akt/cyclooxygenase-2/Mcl-1 pathway renders lung cancer cells resistant to apoptosis Mol Pharmacol 77 416 423 1:CAS:528:DC%2BC3cXjt1ent7c%3D 10.1124/mol.109.061226 19933775
15. X Wang W Chen W Zeng, et al. 2008 Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells Mol Cancer Ther 7 1156 1163 1:CAS:528:DC%2BD1cXlvFanu7c%3D 10.1158/1535-7163.MCT-07-2183 18483303
16. C Nakanishi M Toi 2005 Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs Nat Rev Cancer 5 297 309 1:CAS:528:DC%2BD2MXivVars7Y%3D 10.1038/nrc1588 15803156 (Pubitemid 40488635)
17. W Chen X Wang L Bai X Liang J Zhuang Y Lin 2008 Blockage of NF-kappaB by IKKbeta- or RelA-siRNA rather than the NF-kappaB super-suppressor IkappaBalpha mutant potentiates adriamycin-induced cytotoxicity in lung cancer cells J Cell Biochem 105 554 561 1:CAS:528:DC%2BD1cXht1elu7bO 10.1002/jcb.21856 18636537
18. X Wang W Chen Y Lin 2007 Sensitization of TNF-induced cytotoxicity in lung cancer cells by concurrent suppression of the NF-kappaB and Akt pathways Biochem Biophys Res Commun 355 807 812 1:CAS:528:DC%2BD2sXisVWis7w%3D 10.1016/j.bbrc.2007.02.030 17316570 (Pubitemid 46330225)
19. HN He X Wang XL Zheng, et al. 2010 Concurrent blockade of the NF-kappaB and Akt pathways potently sensitizes cancer cells to chemotherapeutic-induced cytotoxicity Cancer Lett 295 38 43 1:CAS:528:DC%2BC3cXntVSmsb4%3D 10.1016/j.canlet.2010.02.011 20207071
20. L Neckers 2007 Heat shock protein 90: the cancer chaperone J Biosci 32 517 530 1:CAS:528:DC%2BD2sXmsFamu7k%3D 10.1007/s12038-007-0051-y 17536171 (Pubitemid 46708702)
21. X Wang W Ju J Renouard J Aden SA Belinsky Y Lin 2006 17-allylamino-17- demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathway Cancer Res 66 1089 1095 1:CAS:528:DC%2BD28XlsFOgtg%3D%3D 10.1158/0008-5472.CAN-05-2698 16424045 (Pubitemid 43165977)
22. J Lewis A Devin A Miller, et al. 2000 Disruption of hsp90 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-kappaB activation J Biol Chem 275 10519 10526 1:CAS:528:DC%2BD3cXisFWjtLY%3D 10.1074/jbc.275.14.10519 10744744 (Pubitemid 30202115)
23. SL Petersen L Wang A Yalcin-Chin, et al. 2007 Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis Cancer Cell 12 445 456 1:CAS:528:DC%2BD2sXhtl2nurrN 10.1016/j.ccr.2007.08.029 17996648 (Pubitemid 350064365)
24. E Varfolomeev JW Blankenship SM Wayson, et al. 2007 IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis Cell 131 669 681 1:CAS:528:DC%2BD2sXhsVSgurzF 10.1016/j.cell.2007.10.030 18022362 (Pubitemid 350087204)
25. JE Vince WW Wong N Khan, et al. 2007 IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis Cell 131 682 693 1:CAS:528: DC%2BD2sXhsVSgur3N 10.1016/j.cell.2007.10.037 18022363 (Pubitemid 350103599)
26. MJ Bertrand S Milutinovic KM Dickson, et al. 2008 cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination Mol Cell 30 689 700 1:CAS:528:DC%2BD1cXnvFWnt74%3D 10.1016/j.molcel.2008.05.014 18570872 (Pubitemid 351818251)
27. L Wang F Du X Wang 2008 TNF-alpha induces two distinct caspase-8 activation pathways Cell 133 693 703 1:CAS:528:DC%2BD1cXmsVOru78%3D 10.1016/j.cell.2008.03.036 18485876 (Pubitemid 351636305)
28. L Bai W Chen X Wang W Ju S Xu Y Lin 2009 Attenuating Smac mimetic compound 3-induced NF-kappaB activation by luteolin leads to synergistic cytotoxicity in cancer cells J Cell Biochem 108 1125 1131 1:CAS:528: DC%2BD1MXhsV2gsLrM 10.1002/jcb.22346 19739098
29. L Bai W Chen X Wang H Tang Y Lin 2009 IKKβ-mediated nuclear factor-κB activation attenuates smac mimetic-induced apoptosis in cancer cells Mol Cancer Ther 8 1636 1645 1:CAS:528:DC%2BD1MXntVKgtrk%3D 10.1158/1535-7163.MCT-09-0068 19509265
30. RD Ramirez S Sheridan L Girard, et al. 2004 Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins Cancer Res 64 9027 9034 1:CAS:528:DC%2BD2cXhtVOmsLjK 10.1158/0008-5472.CAN-04-3703 15604268 (Pubitemid 39665513)
31. W Ju X Wang H Shi W Chen SA Belinsky Y Lin 2007 A critical role of luteolin-induced reactive oxygen species in blockage of tumor necrosis factor-activated nuclear factor-kappaB pathway and sensitization of apoptosis in lung cancer cells Mol Pharmacol 71 1381 1388 1:CAS:528:DC%2BD2sXlslSis70%3D 10.1124/mol.106.032185 17296806 (Pubitemid 46658691)
32. Y Lin Q Yang X Wang ZG Liu 2006 The essential role of the death domain kinase receptor-interacting protein in insulin growth factor-I-induced c-Jun N-terminal kinase activation J Biol Chem 281 23525 23532 1:CAS:528: DC%2BD28XotVCmtL0%3D 10.1074/jbc.M601487200 16793775 (Pubitemid 44274127)
33. Y Lin J Ryan J Lewis MA Wani JB Lingrel ZG Liu 2003 TRAF2 exerts its antiapoptotic effect by regulating the expression of Kruppel-like factor LKLF Mol Cell Biol 23 5849 5856 1:CAS:528:DC%2BD3sXmt1Srtb4%3D 10.1128/MCB.23.16. 5849-5856.2003 12897154 (Pubitemid 36951346)
34. CJ Norbury B Zhivotovsky 2004 DNA damage-induced apoptosis Oncogene 23 2797 2808 1:CAS:528:DC%2BD2cXivFKmsLY%3D 10.1038/sj.onc.1207532 15077143 (Pubitemid 38638843)
35. F Meng L Liu PC Chin SR D'Mello 2002 Akt is a downstream target of NF-kappa B J Biol Chem 277 29674 29680 1:CAS:528:DC%2BD38XmsVKitbs%3D 10.1074/jbc.M112464200 12052823
36. SL Petersen M Peyton JD Minna X Wang 2010 Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression Proc Natl Acad Sci USA 107 11936 11941 1:CAS:528:DC%2BC3cXovVartLg%3D 10.1073/pnas.1005667107 20547836
37. RK Ramanathan DL Trump JL Eiseman, et al. 2005 Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17- demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers Clin Cancer Res 11 3385 3391 1:CAS:528:DC%2BD2MXjslOqt70%3D 10.1158/1078-0432.CCR-04-2322 15867239 (Pubitemid 40627891)
38. L Neckers K Neckers 2005 Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics-an update Expert Opin Emerg Drugs 10 137 149 1:CAS:528:DC%2BD2MXislCrt7o%3D 10.1517/14728214.10.1.137 15757409 (Pubitemid 40293075)